Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-033 in Healthy Volunteers and Age-related Macular Degeneration
NCT07662096Phase 1Recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, randomised trial of ARO-033 in age-related macular degeneration (AMD) (4 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Treatment-emergent Adverse Events. Started Jun 2026; status: recruiting.
02
Drugs
ARO-033
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT07662096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662096.